RankingsPricing
  1. US-listed companies
  2. ALNYLAM PHARMACEUTICALS, INC.
  3. Financials
  4. Common stock and paid-in capital

ALNYLAM PHARMACEUTICALS, INC.ALNY

Market cap
$56.9B
P/E ratio
SummaryFinancials
Period EndCommon stock and paid-in capital (Million USD)YoY (%)
Dec 31, 20241+4.27%
Dec 31, 20221+3.16%
Dec 31, 20211+3.26%
Dec 31, 20201+3.74%
Dec 31, 20191+10.98%
Dec 31, 20181+1.40%
Dec 31, 20171+16.07%
Dec 31, 20161+0.94%
Dec 31, 20151+10.23%
Dec 31, 20141+21.19%
Dec 31, 20131+21.33%
Dec 31, 20121+22.95%
Dec 31, 20110+0.95%
Dec 31, 20100

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)